Abstract
Since the discovery that activating mutations of the Ras GTPase were associated with 30% or more of human cancers, the RAF/MEK/ERK pathway has been the focus of intense drug discovery effort. Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise.
MeSH terms
-
Animals
-
Benzamides / chemistry
-
Benzamides / therapeutic use
-
Benzenesulfonates / chemistry
-
Benzenesulfonates / therapeutic use
-
Clinical Trials as Topic
-
Diphenylamine / analogs & derivatives
-
Diphenylamine / chemistry
-
Diphenylamine / therapeutic use
-
Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors*
-
Extracellular Signal-Regulated MAP Kinases / metabolism
-
Humans
-
Molecular Structure
-
Neoplasms / drug therapy*
-
Neoplasms / physiopathology
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins c-raf / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-raf / metabolism
-
Pyridines / chemistry
-
Pyridines / therapeutic use
-
Signal Transduction / drug effects*
-
Signal Transduction / physiology
-
Sorafenib
Substances
-
Benzamides
-
Benzenesulfonates
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Pyridines
-
Niacinamide
-
mirdametinib
-
Diphenylamine
-
Sorafenib
-
Proto-Oncogene Proteins c-raf
-
Extracellular Signal-Regulated MAP Kinases